Naftopidil

Research use only, not for human use.

Naftopidil (INN, marketed under the brand name Flivas) is an antihypertensive drug which acts as a selective α1-adrenergic receptor antagonist or alpha blocker.

Naftopidil (INN, marketed under the brand name Flivas) is an antihypertensive drug which acts as a selective α1-adrenergic receptor antagonist or alpha blocker.(In Vitro):Naftopidil suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.Naftopidil (10 μM for PCa cells, 0.1-10 μM for PrSC; 3 days) shows growth inhibitory effects on PCa cells and PrSC.Naftopidil (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increases the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.(In Vivo):Naftopidil (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model.

Naftopidil suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.Naftopidil (10 μM for PCa cells, 0.1-10 μM for PrSC; 3 days) shows growth inhibitory effects on PCa cells and PrSC.Naftopidil (50 μM for E9 cells, 25 μM for PrSC; 48 hours) increases the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.Cell Proliferation Assay Cell Line:PCa cells, PrSC Concentration:10 μM (PCa cells); 0.1 μM, 1 μM, 10 μM (PrSC)Incubation Time:3 days Result:Exhibited growth inhibitory effects on PCa cells and PrSC in dose-dependent manners.Western Blot Analysis Cell Line:PCa cells, PrSC Concentration:50 μM (E9 cells), 25 μM (PrSC)Incubation Time:48 hours Result:Increased the level of cell-cycle regulatory protein p27 in E9 cells, but not PrSC.

Naftopidil (10 mg/kg; p.o; daily; for 28 days) decreases microvessel density (MVD) in E9+PrSC tumors mice model. Animal Model:Male athymic mice (7-8 weeks), with E9+PrSC xenograft Dosage:10 mg/kg Administration:Oral administration, daily, for 28 days Result:Decreased tumor weights.

Naftopidil | BM-15275 | KT-611 | BM 15275 | KT 611 | BM15275 | KT611 | Flivas

Endocrinology/Hormones

Adrenergic Receptor

α1A-adrenergic receptor| α1B-adrenergic receptor| α1D-adrenergic receptor

Cardiovascular Disease

——

57149-07-2

392.49

C24H28N2O3

>98% (HPLC)

DMSO: 79 mg/mL (201.27 mM)

OC(COC1=C2C=CC=CC2=CC=C1)CN3CCN(C4=CC=CC=C4OC)CC3

1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol

(-20℃)

With Ice Pack

≥ 2 years